Adamini, S., Maarse, H., Versluis, E. and Light, D.W. (2009) Policy making on data exclusivity in the European Union: From industrial interests to legal realities. Journal of Health Politics, Policy and Law 34: 979–1010.CrossRefGoogle Scholar
Andrews, E.L. (2005) Hitting the tax-break jackpot. The New York Times, 1 February: C1–C2.
Angell, M. (2004) The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House.Google Scholar
Barton, J. and Emanuel, E. (2005) The patent-based pharmaceutical development process: Rationale, problems, and potential reforms. Journal of American Medical Association 294: 2075–2082.CrossRefGoogle Scholar
Berenson, A. (2005) Tax break gives huge benefits to drugmakers. New York Times, 8 May.
Boston Consulting Group. (2001) A Revolution in R&D. Boston, MA: Boston Consulting Group.
Butler, D. (2010) Cash crisis looms for vaccine drive. Nature 464: 338.CrossRefGoogle Scholar
Canadian Coordinating Office for Health Technology Assessment. (1997) Guidelines for Economic Evaluation of Pharmaceuticals, 2nd Edition. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment.
Carpenter, D., Zucker, E.J. and Avorn, J. (2008) Drug-review deadlines and safety problems. New England Journal of Medicine 358: 1354–1361, (1359: 1396–1398).CrossRefGoogle Scholar
DiMasi, J.A., Hansen, R.W. and Grabowski, H. (2003a) The price of innovation: New estimates of drug development costs. Journal of Health Economics 22: 151–185.CrossRefGoogle Scholar
DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003b) The price of innovation: New estimates of drug development costs, Appendix B, pp. 1–6. Tufts University (unpublished).
DiMasi, J.A., Hansen, R.W., Grabowski, H.G. and Lasagna, L. (1991) Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10: 107–142.CrossRefGoogle Scholar
EFPIA. (2010) The Pharmaceutical Industry in Figures. Brussels, Belgium: European Federation of Pharmaceutical Industries and Associations.
Engelberg, A.B. (1982) Patent term extension: An overreaching solution to a nonexistent problem. Health Affairs 1 (2): 34–45.CrossRefGoogle Scholar
European Commission for Competition. (28 November 2008) Pharmaceutical Sector Inquiry – Preliminary Report. Brussels, Belgium: European Commission for Competition.
Farlow, A. (2005) Accelerating the innovation of vaccines. Innovation Strategy Today 1 (2): 66–202.Google Scholar
Fisher, J.A. (2009) Medical Research for Hire: the Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press.Google Scholar
Frew, S.E., Kettler, H.E. and Singer, P.A. (2008) The Indian and Chinese health biotechnology industries: Potential champions of global health? Health Affairs 27 (4): 1029–1041.CrossRefGoogle Scholar
General Accounting Office. (2003) Technology Transfer: NIH-Private Sector Partnership in the Development of Taxol, (No. GAO-03-829). Washington DC: General Accounting Office.
Goozner, M. (2004) The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkeley, CA: University of California Press.Google Scholar
Grabowski, H. (ed.) (1976) Drug Regulation and Innovation: Empirical Evidence and Policy Options. Washington DC: American Enterprise Institute.Google Scholar
Grabowski, H.G. (1978) Drug Regulation and Innovation. Washington DC: American Enterprise Institute for Public Policy Research.Google Scholar
Hansen, R.W. (1979) The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory changes. In: R.I. Chien (ed.) Issues in Pharmaceutical Economics. Lexington, MA: Lexington Books, pp. 151–187.Google Scholar
Harris, G. (2001) Health costs of developing new medicine swelled to $802 million, research study reports. Wall Street Journal
, accessed November 2010.
Keyhani, S., Diener-West, M. and Powe, N. (2006) Are development times for pharmaceuticals increasing or decreasing? Health Affairs 25 (2): 461–468.CrossRefGoogle Scholar
Kremer, M. and Glennerster, R. (2004) Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton, NJ: Princeton University Press.Google Scholar
Le Fanu, J. (1999) The Rise and Fall of Modern Medicine. New York: Carroll & Graf Publishers.Google Scholar
Light, D.W. (2006) Basic research funds to discover important new drugs: Who contributes how much? In: M.A. Burke (ed.) Monitoring the Financial Flows for Health Research 2005: Behind the Global Numbers. Geneva, Switzerland: Global Forum for Health Research, pp. 27–43.Google Scholar
Light, D.W. (2007) Is G8 putting profits before the world's poorest children? The Lancet 370: 297–298.CrossRefGoogle Scholar
Light, D.W. (2009) Advanced Market Commitments: Current Realities and Alternate Approaches. Amsterdam, the Netherlands: HAI Europe/Medico International Publication.Google Scholar
Light, D.W. (ed.) (2010) The Risk of Prescription Drugs. New York: Columbia University Press.CrossRefGoogle Scholar
Light, D.W., Andrus, J. and Warburton, R. (2009) Estimated costs of research and development of rotavirus vaccines. Vaccine 27: 6627–6633.CrossRefGoogle Scholar
Light, D.W. and Lexchin, J. (2005) Foreign free riders and the high price of US medicines. BMJ 331: 958–960.CrossRefGoogle Scholar
Love, J. (2003) Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines. Washington DC: Consumer Project on Technology.Google Scholar
McGoey, L. (2009) Pharmaceutical controversies and the performative value of uncertainty. Science as Culture 18: 151–164.CrossRefGoogle Scholar
Mitsuya, H., Winhold, K., Yarchoan, R., Bolognesi, D. and Broder, S. (1989) Credit government scientists with developing anti-AIDS drugs (letter). New York Times.
Moran, M. (2005) A breakthrough in R&D for neglected diseases: New ways to get the drugs we need. PLoS Medicine 2 (9): e302.CrossRefGoogle Scholar
Moran, M . et al
(2007) The Malaria Product Pipeline: Planning for the Future. Sydney, Australia: The George Institute for International Health.Google Scholar
Morgan, S.G . et al
(2005) ‘Breakthrough’ drugs and growth in expenditure on prescription drugs in Canada. BMJ 331: 815–816.CrossRefGoogle Scholar
National Institute for Health Care Management. (2000) Prescription Drugs and Intellectual Property Protection. Washington DC: National Institute for Health Care Management.
National Science Foundation. (2003) Research and Development in Industry: 2000. Arlington, VA: National Science Foundation, Division of Science Resources Statistics.
Olson, M.K. (2004) Are novel drugs more risky for patients than less novel drugs? Journal of Health Economics 23: 1135–1158.CrossRefGoogle Scholar
Patented Medicine Prices Review Board. (2002) A Comparison of Pharmaceutical Research and Development Spending, (No. PMPRB Study Series S-0217). Ottawa, Canada: PMPRB.
Pharmaceutical R&D Policy Project. (2005) The New Landscape of Neglected Disease Drug Development. London: The Wellcome Trust and London School of Economics and Political Science.
Pharmaceutical Research and Manufacturers of America. (2002) Pharmaceutical Industry Profile 2002. Washington DC: Pharmaceutical Research and Manufacturers of America.
PhRMA. (2009) Pharmaceutical Industry Profile 2009. Washington DC: Pharmaceutical Research and Manufacturers of America.
Plahte, J. (2005) Tiered pricing of vaccines: A win-win-win situation, not a subsidy. The Lancet Infectious Diseases 5 (1): 58–63.CrossRefGoogle Scholar
Public Citizen. (2001) Rx R&D Myths: The Case Against the Drug Industry's R&D ‘Scare Card’. Washington DC: Public Citizen.
Russell, K.B., Gold, M.R., Siegel, J.E., Daniels, N. and Weinstein, M.C. (1996) The role of cost-effectiveness analysis in health and medicine: Panel on cost-effectivess in health and medicine. Journal of American Medical Association 276: 1172–1177.CrossRefGoogle Scholar
Tax Policy Center. (2002) Marginal rates of the Federal Corporation Income Tax, 1942–2002. Washington DC: Tax Policy Center.
United States Office of Management and Budget. (2003) Guidelines and Discount Rates for Benefit-Cost Analysis of Federal Programs. Washington DC: United States Office of Management and Budget.
US Food and Drug Administration. (2004) NDAs Approved in Calendar Years1990–2003 by Therapeutic Potential and Chemical Types. Washington DC: U.S. Food and Drug Administration.
US Office of Technology Assessment. (1993) Pharmaceutical R&D: Costs, Risks and Rewards, (No. NTIS #PB93-163376). Washington DC: Office of Technology Assessment.
Wardell, W.M. and Lasagna, L. (eds.) (1975) Regulation and Drug Development. Washington DC: American Enterprise Institute.Google Scholar
Waxman, H., Durbin, R.J. and Kennedy, E.M. (2006) New GAO Analysis of Drug Development Refutes Industry Myths. Washington DC: U.S. Congress.Google Scholar
Weinstein, M.C., Siegel, J.E., Gold, M.R., Kamlet, M.S. and Russell, L.B. (1996) Recommendations of the panel on cost-effectiveness in health and medicine. Journal of American Medical Association 276: 1253–1258.CrossRefGoogle Scholar